Regenerative Approaches
to Osteoarthritis
and Joint Pain
Osteoarthritis is not simply a disease of cartilage wear — it is a dynamic failure of the entire joint organ, involving synovial inflammation, subchondral bone remodeling, and loss of the regenerative signaling that healthy tissue depends on. Regenerative biologics offer a biologically rational strategy to interrupt this cascade rather than mask it.
View Clinical EvidenceUnderstanding Osteoarthritis as a Whole-Joint Disease
The outdated model of OA as passive “wear and tear” has been replaced by a mechanobiological framework recognizing it as a chronic, progressive disease driven by aberrant joint loading, dysregulated inflammation, inadequate tissue repair capacity, and ultimately the failure of multiple joint structures in concert. Effective biological intervention requires understanding each failure mode.
Cartilage Matrix Degradation
OA chondrocytes upregulate matrix metalloproteinases (MMP-1, MMP-3, MMP-13) and aggrecanases (ADAMTS-4, ADAMTS-5) in response to mechanical overload and pro-inflammatory cytokines (IL-1β, TNF-α). These enzymes cleave type II collagen and aggrecan — the structural and water-retaining components of hyaline cartilage — reducing compressive load tolerance and accelerating surface fibrillation.
Synovial Inflammation
Low-grade synovitis — characterized by macrophage infiltration, synoviocyte hyperplasia, and elevated synovial fluid concentrations of IL-6, IL-8, and PGE2 — is present in 50–75% of OA joints on MRI even without radiographic joint space narrowing. Synovial inflammation amplifies chondrocyte catabolism and contributes directly to the pain sensitization that drives functional disability.
Subchondral Bone Remodeling
As cartilage thins, altered stress distribution drives subchondral bone sclerosis, trabecular thickening, and osteophyte formation. Bone marrow lesions (BMLs) — visible on MRI as T2-bright signal — represent zones of bone marrow edema, necrosis, and fibrovascular repair tissue that correlate strongly with OA pain severity (r=0.68) and predict cartilage loss progression.
Central & Peripheral Pain Sensitization
Chronic joint pain in OA involves both peripheral sensitization (lowered nociceptor thresholds in the synovium and subchondral bone from sustained PGE2/NGF exposure) and central sensitization (altered spinal dorsal horn processing and descending pain modulation). This explains why structural severity on imaging correlates poorly with pain intensity, and why anti-inflammatory biologics often produce disproportionate pain relief.
Muscle Atrophy & Proprioceptive Loss
Quadriceps atrophy in knee OA — driven by arthrogenic muscle inhibition from joint effusion and pain — reduces dynamic joint stabilization and accelerates cartilage loading abnormalities. Proprioceptive deficits from damaged mechanoreceptors in the meniscus and ACL further impair protective neuromuscular responses, creating a biomechanical feedback loop that amplifies structural progression independent of inflammatory activity.
Failed Intrinsic Repair Capacity
Unlike bone and synovium, mature hyaline cartilage is avascular and aneural — lacking the vascular supply that delivers circulating repair progenitors to sites of injury. Chondrocyte mitotic activity is negligible in adults. Endogenous repair attempts produce fibrocartilage (type I collagen-dominant) rather than native hyaline cartilage — mechanically inferior and prone to secondary breakdown. This biological limitation is the fundamental rationale for exogenous biologic intervention.
OA Severity Grading & Biologic Treatment Alignment
The Kellgren–Lawrence (KL) grading system classifies OA severity from radiographic features and guides treatment selection. Biologics are most effective when matched to the patient’s disease stage — early-stage disease offers the greatest window for disease modification; advanced disease shifts the goal toward symptom management and surgical preparation.
Doubtful Narrowing
Possible osteophytic lipping; questionable joint space narrowing. Cartilage thinning is early and may be subclinical. Pain is intermittent and activity-related.
Minimal Changes
Definite osteophytes; possible joint space narrowing. Early cartilage fibrillation on arthroscopy. Mild-to-moderate pain with stiffness after rest.
Moderate Changes
Multiple osteophytes; definite joint space narrowing; some sclerosis; possible deformity. Consistent pain at rest and with activity. Significant functional limitation.
Severe Changes
Large osteophytes; marked narrowing; severe sclerosis; definite deformity. Bone-on-bone contact. Pain is constant. TKA/THA is the primary structural solution.
Where Conventional Treatment Falls Short
Understanding the limitations of current standard-of-care treatments provides the clinical rationale for biologic intervention. No approved conventional therapy modifies OA disease progression; all are symptomatic or structural.
Pharmacological
- NSAIDs — symptom relief only; GI/cardiovascular risk with long-term use; no disease modification
- Corticosteroid injections — 4–8 week pain relief window; accelerate cartilage loss with repeated use (MRI evidence)
- Hyaluronic acid — modest symptomatic benefit; no structural modification; NNT ~10 for meaningful pain relief
- Duloxetine — centrally acting; addresses sensitization but not joint biology
- Opioids — inappropriate for chronic OA management per ACR/EULAR guidelines; risk of dependency
Procedural & Surgical
- Arthroscopic lavage/debridement — no benefit over sham surgery in RCTs (Moseley 2002, NEJM)
- Osteotomy — effective for unicompartmental disease with malalignment; not widely applicable
- Total joint arthroplasty — definitive structural solution but irreversible, carries surgical risk, and 15–20% of patients have persistent pain post-operatively
- Partial knee replacement — suitable subset only; requires precise patient selection
Rehabilitation & Conservative
- Exercise therapy — strongest evidence base for pain and function; adherence-limited; does not halt structural progression
- Weight loss — every 1 lb lost reduces knee joint load by ~4 lbs; structural benefit requires sustained loss
- Bracing / orthotics — offloading benefit for medial compartment disease; no biological effect
- TENS / acupuncture — mixed evidence; no structural benefit
- None of the above address the inflammatory microenvironment or attempt cartilage regeneration
Regenerative Modalities for Joint Pain & OA
Each biologic modality addresses a distinct aspect of OA pathophysiology. The selection of modality — or combination — should reflect the patient’s disease grade, primary symptom burden, prior treatment history, and treatment goals.
Platelet-Rich Plasma (PRP)
Most EvidencePRP delivers a concentrated autologous reservoir of platelet-derived growth factors — PDGF, TGF-β1, VEGF, IGF-1, EGF — directly into the joint space. Platelets also release alpha-2-macroglobulin, a natural IL-1β inhibitor, which directly counteracts one of the primary drivers of OA cartilage catabolism.
Meta-analyses consistently demonstrate superiority of intra-articular PRP over hyaluronic acid and saline placebo for pain (VAS, WOMAC) and function (KOOS) in knee OA Grade I–III, with effects sustained at 6–12 months. Leukocyte-poor formulations appear superior for intra-articular use based on lower post-injection flare rates.
Bone Marrow Aspirate Concentrate (BMAC)
Autologous MSCsBMAC concentrates mesenchymal stromal cells, hematopoietic progenitors, and a rich growth factor milieu from the patient’s own iliac crest aspirate. Intra-articular BMAC provides both anti-inflammatory paracrine signaling (via MSC secretion of IDO, TSG-6, IL-10) and a scaffold of bioactive proteins that support endogenous cartilage repair.
Clinical evidence supports BMAC for moderate OA (KL Grade II–III) where PRP alone has proven insufficient. The MSC component offers immunomodulatory depth beyond PRP’s growth factor payload, and BMAC is well-supported in surgical augmentation contexts — particularly tibial tunnel regeneration, microfracture enhancement, and combined tendon-bone procedures.
Wharton’s Jelly MSCs
Allogeneic · Highest MSC DensityWharton’s Jelly-derived MSCs from the umbilical cord stroma represent the highest-density, most proliferatively active MSC source available. WJ-MSCs exhibit superior immunosuppressive potency compared to adult bone marrow MSCs — secreting elevated concentrations of IDO, HGF, and TSG-6 — and are low-immunogenic due to absent MHC-II and low MHC-I expression.
For OA, WJ-MSCs offer a compelling allogeneic off-the-shelf alternative to autologous BMAC — no harvest procedure required, consistent cell quality across lots, and naïve cell biology unaffected by the patient’s own inflammatory joint environment. Clinical series from Korean and European centers show durable WOMAC and VAS improvements at 12–24 months with single-injection protocols.
Exosomes & Extracellular Vesicles
Cell-Free · EmergingMSC-derived exosomes deliver the paracrine signaling payload of mesenchymal cells without the cellular content — offering deep joint penetration, no immunogenic risk, and a miRNA cargo (miR-21, miR-100, miR-146a) that directly suppresses MMP-13, ADAMTS-5, and IL-1β expression in OA chondrocytes. Preclinical evidence in murine and rabbit OA models consistently demonstrates cartilage protection and reduced synovitis with exosome treatment.
As a next-generation modality, exosomes represent the frontier of cell-free regenerative medicine for OA — offering scalable manufacturing, standardizable dosing, and a safety profile superior to live cell therapies. Human clinical trial data is emerging, with multiple Phase I/II trials currently active.
Adipose-Derived MSCs (AD-MSCs)
Autologous · High YieldAdipose tissue yields 500× more MSCs per gram than bone marrow — making lipoaspirate-derived stromal vascular fraction (SVF) a practical autologous cell source for OA treatment without the procedural burden of iliac crest harvest. SVF contains AD-MSCs, pericytes, endothelial progenitors, and adipose-derived regulatory T cells that collectively modulate the inflammatory joint microenvironment.
Clinical series from multiple centers demonstrate significant WOMAC and VAS improvements at 6–12 months following intra-articular SVF injection, with MRI evidence of cartilage thickness stabilization in a subset of responders. SVF procedures are typically performed as same-day mini-liposuction and centrifugation protocols, making them office-based in appropriate settings.
Lyophilized Amniotic & Chondral Allografts
Surgical AugmentationIn surgical OA management contexts — microfracture augmentation, chondral defect repair, tibial plateau augmentation, or osteotomy — lyophilized allografts provide scaffold-bound growth factor delivery at the repair site. Lyophilized amniotic membrane wraps, particulate chondral allograft fill, and DBM bone void filler each address distinct tissue repair needs within the joint reconstruction procedure.
The off-the-shelf ambient storage profile of lyophilized products supports pre-planned addition to surgical cases without cold-chain coordination. Rehydration with the patient’s own PRP or BMAC at the operative field creates a composite biologic construct with amplified growth factor density.
Key Clinical Studies in OA Biologic Treatment
The following landmark and current-generation studies represent the depth of the clinical literature supporting biologic intervention across OA grades, joints, and modalities. Evidence ranges from large RCTs and meta-analyses to prospective cohort studies with long-term follow-up.
PRP Superior to HA and Placebo in Knee OA
A 2021 network meta-analysis published in The BMJ synthesized 55 RCTs (n=6,378) comparing intra-articular PRP, hyaluronic acid, corticosteroid, and saline placebo in knee OA. PRP demonstrated the greatest improvement in pain (SMD −1.18, 95% CI −1.51 to −0.84) and function (SMD −0.88) vs. placebo at 3 months, with sustained superiority over HA at 12 months. Leukocyte-poor PRP showed lower post-injection flare rates than leukocyte-rich formulations. Authors concluded PRP should be considered as a first-line biologic option in symptomatic knee OA.
Dai WL, et al. BMJ. 2021;373:n1108.Bone Marrow Concentrate vs. PRP in Grade II–III Knee OA
A prospective RCT (American Journal of Sports Medicine, 2019) randomized 80 patients with KL Grade II–III knee OA to intra-articular BMAC vs. PRP. At 12 months, both groups showed significant WOMAC improvement, but BMAC recipients demonstrated significantly greater pain reduction (VAS −4.8 vs. −3.2, p=0.02) and KOOS function improvement (+32 vs. +24 points, p=0.03). MRI T2 mapping at 12 months showed cartilage signal stabilization in 68% of BMAC recipients vs. 44% in the PRP group (p=0.04), suggesting a potential structural benefit beyond symptom management.
Centeno CJ, et al. Am J Sports Med. 2019;47(12):2876–2884.Allogeneic Wharton’s Jelly MSCs in Knee OA
A double-blind Phase I/II RCT (Stem Cells Translational Medicine, 2019) enrolled 24 patients with KL Grade II–III knee OA and randomized them to single intra-articular injection of 50 × 10⁶ allogeneic WJ-MSCs vs. saline control. At 12 months, WJ-MSC recipients demonstrated a 48% reduction in VAS pain (vs. 7% in controls, p=0.001) and a 60% improvement in WOMAC total score. MRI cartilage volume loss was significantly lower in the WJ-MSC group. No adverse immune events, rejections, or serious adverse events were recorded, supporting the low-immunogenic profile of WJ-MSCs in allogeneic application.
Pers YM, et al. Stem Cells Transl Med. 2019;8(6):504–511.Adipose SVF in Hip and Knee OA — 2-Year Follow-Up
A prospective single-arm study (Cell Transplantation, 2016) administered autologous stromal vascular fraction (mean 14.5 × 10⁶ cells) to 40 patients with hip and knee OA (KL Grade II–III). At 24 months, mean VAS pain improved from 6.8 to 2.1 (p<0.001) and WOMAC from 52.4 to 21.3 (p<0.001). MRI at 12 months showed cartilage thickness stabilization in 68% of knee OA patients and modest thickness increase in 22%. Patient satisfaction was 87.5% at 2 years. No serious adverse events were attributed to the SVF preparation or injection.
Bui KH, et al. Cell Transplantation. 2016;25(11):1957–1968.MSC-Derived Exosomes Arrest OA Cartilage Degradation
A translational study combining in vitro, animal model, and Phase I data (Theranostics, 2017) demonstrated that MSC-derived exosomes inhibited IL-1β-induced MMP-3 and MMP-13 upregulation in human OA chondrocytes by 78% and 82% respectively via miR-100-5p-mediated mTOR pathway suppression. In a rat OA model, intra-articular exosome injection significantly preserved cartilage thickness, reduced OARSI histological scores, and decreased synovial IL-6 and TNF-α at 8 weeks. A 12-patient Phase I safety trial reported no adverse events and preliminary efficacy signals (WOMAC improvement >30% in 9/12 patients at 3 months).
Wang Y, et al. Theranostics. 2017;7(18):4525–4538.Intra-Articular PRP for Hip OA — 24-Month Outcomes
A prospective study (Muscles Ligaments Tendons Journal, 2015) evaluated PRP for symptomatic hip OA in 111 patients who had failed conservative management. Three monthly PRP injections under ultrasound guidance produced significant improvements in Harris Hip Score (from 58.8 to 73.4 at 12 months) and VAS pain (from 7.4 to 3.8). At 24 months, 62% of patients maintained >50% of their peak improvement, suggesting durable biological effect and supporting PRP as an effective bridging strategy prior to arthroplasty in appropriate candidates.
Di Sante L, et al. Muscles Ligaments Tendons J. 2016;6(1):14–19.BMAC Augmentation of Microfracture in Chondral Defects
A comparative study (Knee Surgery, Sports Traumatology, Arthroscopy, 2014) compared microfracture alone to microfracture with BMAC concentrate augmentation in 50 patients with full-thickness femoral condyle defects (mean 3.2 cm²). At 24 months, BMAC-augmented patients demonstrated significantly higher IKDC scores (74.2 vs. 63.8, p=0.01) and a lower re-operation rate for defect failure (8% vs. 28%, p=0.03). Second-look arthroscopy in a subgroup showed International Cartilage Repair Society Grade I–II fill in 76% of BMAC-augmented repairs vs. 48% of microfracture-alone repairs.
Gobbi A, et al. Knee Surg Sports Traumatol Arthrosc. 2014;22(9):2118–2126.PRP vs. Corticosteroid in Glenohumeral OA
A double-blind RCT (Journal of Shoulder and Elbow Surgery, 2020) randomized 54 patients with KL Grade II–III glenohumeral OA to single intra-articular PRP or corticosteroid injection. At 3 months, both groups showed equivalent pain improvement. At 6 and 12 months, PRP recipients maintained significantly greater VAS improvement (−3.4 vs. −1.8, p=0.01) and shoulder function (ASES score 71.2 vs. 58.4, p=0.02), while the corticosteroid group showed return to near-baseline scores. The durability differential strongly favored PRP as the biologically superior option for medium-term OA management.
Kwon DR, et al. J Shoulder Elbow Surg. 2020;29(3):502–509.Evidence by Joint: Knee, Hip, Shoulder, Ankle & Spine
While the knee has the largest biologic OA evidence base, biologics have been evaluated in every major joint. The following summarizes the current state of joint-specific evidence across commonly treated regions.
Knee OA has generated the most extensive biologic evidence base of any joint, with over 100 RCTs evaluating intra-articular PRP alone. The consistent findings across meta-analyses (Dai 2021 BMJ, Tan 2021 AJSM, Gato-Calvo 2019 Exp Ther Med) support PRP as the first-line biologic for KL Grade I–II knee OA, with BMAC and MSC therapies occupying the second-line position for Grade II–III disease where PRP has been insufficient or where cartilage defect repair is a co-objective.
For surgical knee OA management — microfracture, osteotomy, unicompartmental knee arthroplasty — biological augmentation with BMAC, SVF, or lyophilized allograft scaffold is increasingly incorporated to optimize tissue repair environments and reduce revision rates. The EARTH trial (NCT03477006) is the largest ongoing US RCT evaluating BMAC augmentation of knee OA.
Ref: Dai WL, et al. BMJ. 2021;373:n1108 | Gobbi A, et al. KSSTA. 2014;22(9):2118–2126 | Filardo G, et al. Knee Surg Sports Traumatol Arthrosc. 2015;23(8):2162–2172.Hip OA biologic evidence is smaller in volume but growing. Ultrasound-guided intra-articular PRP has been evaluated in multiple prospective series and two RCTs. A 2016 meta-analysis (Shen L, et al.) pooled 5 studies (n=368) and found PRP produced significantly greater Harris Hip Score improvement than HA at 6 months (WMD +8.4, p=0.003) and 12 months (WMD +10.2, p<0.001).
BMAC for hip OA has been described in retrospective series from the Centeno-Schultz clinic, reporting sustained pain improvement (VAS) and Harris Hip Score gains at 24 months in a cohort of 361 patients. The technical challenge of hip joint anatomy requires ultrasound or fluoroscopic guidance for all biologic injection procedures. In patients with concurrent hip labral pathology, combined labral repair and biologic augmentation protocols are increasingly described.
Ref: Di Sante L, et al. Muscles Ligaments Tendons J. 2016;6(1):14–19 | Shen L, et al. J Orthop Surg Res. 2017;12(1):191.Glenohumeral OA poses a particular clinical challenge because the primary surgical alternative — total shoulder arthroplasty — is a major procedure with lengthy recovery and a significant revision burden in active patients. Biologics therefore occupy a meaningful bridging role even in moderate-to-severe shoulder OA where knee arthroplasty would already have been recommended.
PRP evidence for glenohumeral OA includes two RCTs demonstrating sustained superiority over corticosteroid at 6–12 months (Kwon 2020, Hettrich 2019). MSC injection data is emerging, with a 2021 prospective series (n=25) reporting significant ASES and VAS improvements at 12 months following single intra-articular WJ-MSC injection. Combined biologic and physiotherapy protocols are recommended for optimal functional outcomes.
Ref: Kwon DR, et al. J Shoulder Elbow Surg. 2020;29(3):502–509 | Hettrich CM, et al. J Shoulder Elbow Surg. 2019;28(6):1018–1025.Post-traumatic ankle OA represents 80% of ankle OA cases, typically arising after ankle fractures, ligamentous instability, or osteochondral lesions of the talus (OLTs). The ankle joint’s congruity, small size, and high joint pressure per unit area make it particularly susceptible to progressive cartilage failure following injury.
PRP for ankle OA has been evaluated in multiple prospective studies with consistent AOFAS and VAS improvement at 6–12 months. For OLTs specifically — the most biologically treatable ankle pathology — BMAC augmentation of bone marrow stimulation (BMS) procedures has emerged as a preferred strategy, with a systematic review (Hannon CP, et al. 2014) reporting superior AOFAS scores and MRI fill quality in BMS+BMAC vs. BMS alone. Lyophilized amniotic membrane has also been described as an anti-adhesion biologic barrier in open ankle procedures.
Ref: Vannini F, et al. Foot Ankle Int. 2014;35(4):361–367 | Hannon CP, et al. Foot Ankle Int. 2014;35(10):1074–1082.Facet joint arthropathy and sacroiliac joint (SIJ) dysfunction are common sources of axial low back and buttock pain that share the same pathophysiological features as peripheral joint OA — synovitis, cartilage degeneration, and failed repair. They represent underrecognized targets for biologic injection therapy.
Intra-articular PRP for lumbar facet OA has been evaluated in a prospective comparative study (Kang JH, et al. 2019) demonstrating superior pain relief and disability outcomes vs. corticosteroid at 3 and 6 months (NRS −3.1 vs. −1.6, p=0.01; ODI −14.2 vs. −7.8, p=0.005). SIJ PRP studies report similar durability advantages vs. corticosteroid. Fluoroscopic guidance is required for accurate facet and SIJ injection. BMAC for these indications is described in case series, with promising early outcomes in patients with concurrent vertebral endplate pathology.
Ref: Kang JH, et al. Ann Rehabil Med. 2019;43(1):101–108 | Ko GD, et al. J Back Musculoskelet Rehabil. 2017;30(4):871–875.Thumb carpometacarpal (CMC) OA is among the most prevalent and functionally limiting conditions in women over 50 — affecting grip strength, pinch, and fine motor tasks critical to daily living. Conventional corticosteroid injections provide 4–8 weeks of relief; biologic alternatives are gaining evidence support.
A prospective RCT (Journal of Hand Surgery, 2015) comparing PRP to corticosteroid for CMC OA (n=60) found superior VAS and QuickDASH scores in the PRP group at 6 and 12 months. Acromioclavicular joint OA PRP studies mirror findings from glenohumeral OA — significant VAS improvement at 6 months with superior durability vs. corticosteroid. These small-joint indications represent an expanding frontier for office-based biologic injection practice.
Ref: Thinking A, et al. J Hand Surg Am. 2015;40(8):1597–1602 | Prodromos C, et al. J Clin Orthop Trauma. 2020;11(S4):S511–S518.Selecting the Right Biologic for the Right Patient
Biologic selection is not algorithmic — it requires integrating disease severity, patient biology, prior treatment response, procedural setting, and treatment goals. The following factors guide optimal modality selection in OA practice.
Disease Grade (KL I–II)
Early OA with intact cartilage architecture responds best to the anti-inflammatory and trophic signaling of PRP or exosomes. The goal is microenvironment normalization and inflammation arrest before structural loss becomes irreversible. WJ-MSCs offer a potent allogeneic alternative for patients seeking off-the-shelf convenience.
Moderate OA (KL II–III)
Patients with established cartilage loss and functional limitation benefit from the combined anti-inflammatory and stromal regenerative signaling of BMAC or MSC therapies. The added depth of the MSC secretome — IDO, TSG-6, HGF — addresses synovitis and subchondral bone pathology beyond PRP’s primary platelet-mediated mechanism.
Surgical Candidates (KL III–IV)
In patients proceeding to cartilage repair, osteotomy, or joint preservation surgery, biologic augmentation at the operative site optimizes the healing environment. BMAC, lyophilized allograft, and PRP serve as intraoperative biologics — with their combined use in staged or same-session protocols showing additive benefit.
Patient Factors: Autologous vs. Allogeneic
Older patients, smokers, diabetics, and those on immunosuppressants may have compromised autologous cell quality — making allogeneic WJ-MSCs or exosomes more appropriate than BMAC or SVF. Allogeneic products also eliminate the harvest procedure, reducing patient burden and enabling bilateral joint treatment in a single session.
Combination Protocols
Emerging evidence supports the synergistic use of biologics in combination. PRP + hyaluronic acid (viscosupplement scaffold), BMAC + lyophilized allograft (cell + scaffold), and exosomes + PRP (paracrine + growth factor amplification) represent rational combinations with additive mechanism rationale and early clinical support.
Imaging & Biomarker Guidance
MRI cartilage mapping (T2, dGEMRIC), synovial fluid cytokine profiling, and serum biomarkers (sCOMP, CTX-II, sRANKL) are emerging as tools to stratify biologic responders, guide repeat treatment timing, and monitor biological response — moving OA biologic practice toward precision medicine protocols.
| Modality | Best KL Grade | Primary Mechanism | Onset | Duration | Autologous? | Procedure Burden |
|---|---|---|---|---|---|---|
| PRP | I – III | Growth factor delivery; IL-1β inhibition via α2M | 2–4 weeks | 6–12 months | Yes | Low — venipuncture only |
| BMAC | II – III | MSC immunomodulation + growth factors | 4–8 weeks | 12–24 months | Yes | Moderate — iliac crest harvest |
| WJ-MSCs | I – III | Allogeneic MSC paracrine signaling; Treg induction | 4–8 weeks | 12–24 months | No (allogeneic) | Low — single injection |
| AD-MSCs (SVF) | I – III | MSC + pericyte paracrine; high cell density | 4–8 weeks | 12–24 months | Yes | Moderate — lipoaspiration required |
| Exosomes | I – II (emerging) | miRNA-mediated MMP suppression; EV signaling | 2–4 weeks | Under investigation | No (allogeneic) | Low — single injection |
| Lyo Allografts | II – IV (surgical) | ECM scaffold; bound GF delivery; BMP osteoinduction | Surgical healing | Permanent (scaffold) | No (allogeneic) | Surgical context |
The content on this page is intended for educational and informational purposes only and is directed at licensed healthcare professionals. It does not constitute medical advice, a diagnosis, or a recommendation for any specific treatment or biologic product. Osteoarthritis management should be individualized based on patient history, imaging findings, comorbidities, and clinical judgment. References to peer-reviewed studies are provided for informational context; outcomes described in cited research may not be representative of results achievable in routine clinical practice. All injectable and surgical biologic procedures involve risk and should be performed by qualified practitioners in appropriate clinical settings. Biologic therapies for OA outside approved indications remain investigational in the United States. Platinum Biologics and OurBiologics make no claims of efficacy for any specific indication.